Bourgi, Kassem <br/><br/>
Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.  [electronic resource] 

 -  Journal of the International AIDS Society  04 2020 
 - e25484 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>1758-2652 
<br/><br/><label>Standard No.: </label>10.1002/jia2.25484  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>CD4 Lymphocyte Count<br/>Canada<br/>Cohort Studies<br/>Female<br/>HIV Infections--complications<br/>HIV Integrase Inhibitors--adverse effects<br/>HIV Protease Inhibitors--adverse effects<br/>Heterocyclic Compounds, 3-Ring--adverse effects<br/>Humans<br/>Male<br/>Middle Aged<br/>Oxazines<br/>Piperazines<br/>Pyridones<br/>Reverse Transcriptase Inhibitors--adverse effects<br/>United States<br/>Weight Gain--drug effects